Comerica Bank Has $1.24 Million Holdings in Charles River Laboratories International, Inc. $CRL

Comerica Bank lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 55.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 6,197 shares of the medical research company’s stock after selling 7,829 shares during the period. Comerica Bank’s holdings in Charles River Laboratories International were worth $1,236,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CRL. Principal Financial Group Inc. boosted its holdings in shares of Charles River Laboratories International by 84.5% in the 3rd quarter. Principal Financial Group Inc. now owns 104,719 shares of the medical research company’s stock worth $16,384,000 after acquiring an additional 47,954 shares in the last quarter. Madison Asset Management LLC bought a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $1,935,000. JPMorgan Chase & Co. increased its holdings in Charles River Laboratories International by 14.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 317,179 shares of the medical research company’s stock valued at $49,626,000 after purchasing an additional 40,073 shares in the last quarter. Penserra Capital Management LLC bought a new position in Charles River Laboratories International in the 3rd quarter valued at $533,000. Finally, Cooke & Bieler LP raised its position in Charles River Laboratories International by 0.9% in the 3rd quarter. Cooke & Bieler LP now owns 603,877 shares of the medical research company’s stock valued at $94,483,000 after purchasing an additional 5,100 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 2.0%

CRL stock opened at $177.96 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a twelve month low of $132.58 and a twelve month high of $228.88. The company has a market cap of $8.78 billion, a P/E ratio of -47.33, a PEG ratio of 2.20 and a beta of 1.44. The business has a fifty day moving average of $170.79 and a 200-day moving average of $183.34.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.10. The business had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The firm’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 10.97 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Mizuho set a $192.00 target price on Charles River Laboratories International in a report on Friday. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a report on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target for the company. Evercore reiterated an “outperform” rating and set a $220.00 price target on shares of Charles River Laboratories International in a research report on Friday. JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Finally, Robert W. Baird set a $213.00 price objective on shares of Charles River Laboratories International in a research report on Friday. Eleven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $205.86.

Key Stories Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Charles River reported Q1 EPS of $2.06, ahead of the $1.96 consensus, and revenue of $995.8 million, also above estimates. Reuters article
• Positive Sentiment: Reuters noted steady demand for drug discovery and development services, suggesting the core business is stabilizing. Reuters article
• Neutral Sentiment: Management reaffirmed full-year 2026 EPS guidance of $10.80 to $11.30, which is in line with expectations but not a major upside surprise. Earnings release and transcript
• Negative Sentiment: Investors appear concerned that margin compression and weak organic growth may offset the earnings beat, which helps explain the stock’s weakness. Zacks article
• Negative Sentiment: One recent analyst note downgraded CRL to Sell, citing a strong share rally, muted near-term growth, and longer-term risks. Seeking Alpha article

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.